Colorectal Cancer, Colorectal Cancer Liver Metastasis
Conditions
Keywords
colorectal cancer, colorectal cancer liver metastasis, three-dimensional bioprinting, chemotherapy
Brief summary
The therapeutic regimens of adjuvant and neoadjuvant chemotherapy for colorectal cancer (CRC) remain largely relied on clinical experience, and thus preclinical models are needed to guide individualized medicine. The investigators are going to establish 3D bioprinted CRC models and organoids from surgically resected tumor tissues of CRC patients with or without liver metastases. In vitro 3D models and organoids will be treated with the same chemotherapy drugs with the corresponding patients from whom the models are derived. The sensitivity of chemotherapy drugs will be tested in these two types of in vitro models, and the actual response to chemotherapy in patients will be evaluated. The predictive ability of 3D models for chemotherapy sensitivity in CRC patients will be compared with that of the organoids. This observational study will validate the potential value of 3D bioprinted tumor models in predicting the response to chemotherapy in CRC.
Interventions
PROCEDUREsurgical resection
Surgical resection will be performed for locoregional lesions or liver metastases.
OTHERadjuvant chemotherapy
Regimens of adjuvant chemotherapy are directed by clinical guidance and experience.
OTHERneoadjuvant therapy
Regimens of neoadjuvant chemotherapy are directed by clinical guidance and experience.
Sponsors
Peking University Cancer Hospital & Institute
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
China-Japan Friendship Hospital
Peking Union Medical College Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* More than 18 years old * Diagnosed as colorectal cancer with or without liver metastases before * Pathologically proven colorectal cancer after surgery
Exclusion criteria
* Medical history with other malignancies or serious diseases * Disable to sign the informed consent independently
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Response of 3D tumor models/organoids to the same chemotherapy drugs as the corresponding patients. | 2021.03-2021.12 | The investigators will establish and culture 3D colorectal cancer models and organoids. The 3D models and organoids will be treated with the same chemotherapy drugs as the corresponding patients. The viability of the 3D tumor models and organoids will be observed after treatment and the IC50 of each drug will be calculated. The correlation of 3D model/organoid sensitivity and the patient response will be analyzed. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Response of the colorectal cancer patients to neoadjuvant chemotherapy. | 2021.03-2022.03 | For patients who receive neoadjuvant chemotherapy before surgery, the response to neoadjuvant chemotherapy will be evaluated according to clinical imaging results and the RECIST scores. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Response of the colorectal cancer patients to adjuvant chemotherapy. | 2021.03-2023.12 | The response to adjuvant chemotherapy will be evaluated according to disease free survival (DFS). Regular follow-ups will be conducted, and DFS is difined as the interval between the date of surgery and the date of last follow-up or recurrence/progression. |
Countries
China
Contacts
Primary ContactYilei Mao, MD PhD
Backup ContactLejia Sun, MD
Outcome results
None listed